Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. generics giant and Indian biotech hope their collaboration will position them against Teva/Lonza, Sandoz, and other potential competitors.

You may also be interested in...



Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff

Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.

Mylan Breathes Life Into Its Specialty Pharma Unit

In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.

Mylan Exudes Confidence About Plan For Biogenerics

At a Feb. 21 investor day, Mylan discussed its long-term goals for launching several biosimilars, as well some hard-to-reproduce generic offerings.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel